SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30794777.
- Also identified by DOI 10.1016/j.cell.2019.01.051.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.
Medical subject headings
- Neoplasms
- Oncolytic Virotherapy
- Oncolytic Viruses